Viking Therapeutics, Inc. (VKTX) SEC Filings

Viking Therapeutics, Inc. reports that Dorothy Elizabeth Kelly-Gemmell is a director of the company, and she is not an officer or a ten percent owner. This initial insider report lists no equity holdings or transactions, serving mainly to document her status as a director-level reporting person.

Viking Therapeutics, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer, from time to time, common stock, preferred stock, debt securities, warrants, rights, units and depositary shares. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $500,000,000 of common stock through Stifel, Piper Sandler, Cantor Fitzgerald, Oppenheimer and Canaccord Genuity. Net proceeds from any sales are intended for working capital and general corporate purposes, potentially including acquisitions or business combinations.

As of June 30, 2026, Viking had 116,652,937 shares of common stock outstanding, with authorized capital of 300,000,000 common and 10,000,000 preferred shares. The company is a clinical-stage biopharmaceutical developer focused on metabolic and endocrine disorders, led by its GLP-1/GIP dual agonist VK2735 (injectable and oral), thyroid receptor beta agonist VK2809 for NASH/MASH, VK0214 for X-linked adrenoleukodystrophy, and other early-stage programs. The shelf enhances financing flexibility as these programs advance.

Viking Therapeutics, Inc. reported that President & CEO Brian Lian acquired 221,667 shares of common stock on July 28, 2026 through the vesting of a performance RSU award granted January 3, 2023. On July 29, 2026, 148,517 shares were automatically sold at a weighted-average $33.3153 per share solely to satisfy tax withholding obligations.

Viking Therapeutics, Inc. CFO Greg Zante reported two stock transactions. On July 28, 2026 he acquired 31,667 shares of common stock at no cost when 33.33% of a performance restricted stock unit award granted January 3, 2023 vested after a non‑financial goal was met. On July 29, 2026, 21,217 shares were automatically sold on a non‑discretionary basis solely to satisfy tax withholding obligations, at a weighted‑average price of $33.4704 per share in multiple trades between $33.30 and $33.805.

Viking Therapeutics, Inc. reported that Chief Operating Officer Marianna Mancini received 31,667 shares of common stock on July 28, 2026, upon vesting of a performance restricted stock unit award originally granted on January 3, 2023, after achieving a non-financial performance goal; this vesting represented 33.33% of that award. On July 29, 2026, 18,217 shares were automatically sold on a non-discretionary basis solely to satisfy tax withholding obligations related to this vesting, at a weighted average price of $33.4652 per share, within a price range of $33.28 to $33.805. Reported holdings also include 120 shares acquired on May 20, 2026 under the company’s 2024 Employee Stock Purchase Plan.

Viking Therapeutics, a clinical-stage biotech focused on metabolic and endocrine disorders, reported no revenue and a sharply higher net loss as development spending accelerated. For the six months ended June 30, 2026, net loss was $286.3 million versus $111.2 million a year earlier, driven by a rise in research and development expense to $265.9 million from $101.5 million and general and administrative costs of $30.8 million. For the three-month period, net loss was $128.0 million, or $1.10 per share.

Liquidity remains substantial, with $125.8 million in cash and cash equivalents and $375.9 million in short-term investments at June 30, 2026, despite $239.1 million of operating cash outflow in the first half. The company raised $34.2 million via at-the-market stock sales and had 116.7 million common shares outstanding as of July 15, 2026. Development advanced for obesity candidate VK2735 (Phase 3 injectable and Phase 2 oral data), NASH drug VK2809 (positive 52-week histology), amylin agonist VK3019 (Phase 1 initiated), and X‑ALD candidate VK0214, while a new $500 million share repurchase program over three years was authorized after period-end.

Viking Therapeutics reported second quarter 2026 results alongside an update on its obesity-focused pipeline. Research and development expense rose to $115.8 million and general and administrative expense to $16.9 million, leading to a net loss of $128.0 million, or $1.10 per share. For the first half of 2026, net loss was $286.3 million. Cash, cash equivalents and short-term investments were $502 million at June 30, 2026, compared with $706 million at December 31, 2025.

The company emphasized progress for dual GLP‑1/GIP agonist VK2735, with subcutaneous Phase 3 VANQUISH‑1 and ‑2 obesity trials fully enrolled at approximately 4,500 and 1,000 patients, respectively, and an oral Phase 3 program targeted to begin in 4Q26. A VK2735 maintenance-dosing study is expected to deliver data in 3Q26. Viking also initiated a Phase 1 trial of amylin receptor agonist VK3019 in obesity and strengthened leadership by appointing Hubert Chen, M.D., as chief medical officer and adding Dorothy Gemmell to the board.